Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose provides a source of calories and acts as a substrate for cellular metabolism, replenishing glucose stores. Sodium chloride provides electrolytes for maintenance of osmotic pressure and fluid balance.
Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.
Intravenous rehydration and maintenance of fluid and electrolyte balance,Provision of calories in parenteral nutrition,Treatment of dehydration,Vehicle for drug administration
Treatment of herpes simplex virus (HSV) infections (genital herpes, herpes labialis, herpes simplex encephalitis),Treatment of varicella-zoster virus (VZV) infections (chickenpox, herpes zoster),Neonatal herpes simplex virus infection,Off-label: Prevention of HSV reactivation in immunocompromised patients, treatment of eczema herpeticum
Intravenous; adult dose is 500-1000 m L at a rate of 100-200 m L/hour; frequency depends on fluid and electrolyte needs; maximum rate up to 400 m L/hour in hypovolemic states.
5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.
Not applicable as a terminal half-life; dextrose is rapidly cleared from circulation with a metabolic clearance rate of ~15-20 mg/kg/min under normal conditions. The half-life of infused glucose is approximately 15-30 minutes due to rapid cellular uptake and metabolism.
Terminal elimination half-life in adults with normal renal function is 2.5-3.3 hours. In anuric patients, half-life extends to approximately 19.5 hours, necessitating dosage adjustment in renal impairment.
Dextrose is metabolized via glycolysis and the tricarboxylic acid cycle. Sodium chloride is not metabolized but excreted primarily by the kidneys.
Acyclovir is partially metabolized by aldehyde oxidase and alcohol dehydrogenase to 9-carboxymethoxymethylguanine and other minor metabolites. The majority (62-90%) is excreted unchanged in urine via glomerular filtration and tubular secretion.
Dextrose is metabolized to carbon dioxide and water via glycolysis and the citric acid cycle; essentially eliminated as CO₂ (exhaled) and water (renal, insensible loss). Sodium and chloride are primarily excreted renally (95%) with minor fecal (<2%) and sweat losses.
Primarily renal excretion via glomerular filtration and tubular secretion; approximately 62-91% of an administered dose is recovered unchanged in urine. Fecal excretion is minimal (<2%).
Negligible (<1%); dextrose does not bind to plasma proteins. Sodium and chloride are not protein bound.
9-33% bound to plasma proteins; binding is concentration-independent and predominantly to albumin.
Dextrose distributes into total body water (~0.55 L/kg). Sodium distributes primarily in extracellular fluid (~0.2 L/kg). Volume of distribution for dextrose and electrolytes is not clinically meaningful as a single value.
Approximately 0.7 L/kg, indicating distribution into total body water. Penetrates well into tissues, including cerebrospinal fluid (CSF concentrations ~50% of plasma).
Intravenous: 100%. Oral dextrose: variable but high; not applicable for this formulation, which is IV only. Sodium chloride is completely bioavailable via IV.
Intravenous administration yields 100% bioavailability. Oral bioavailability is 15-30% (not applicable to IV formulation).
For GFR <30 m L/min/1.73 m²: reduce infusion rate to 50-100 m L/hour; monitor serum sodium and glucose; avoid in anuria.
Cr Cl >50 m L/min: no adjustment; Cr Cl 25-50 m L/min: 5-10 mg/kg every 12 hours; Cr Cl 10-25 m L/min: 5-10 mg/kg every 24 hours; Cr Cl <10 m L/min: 2.5-5 mg/kg every 24 hours; hemodialysis: give dose after dialysis.
No specific Child-Pugh based adjustments; use with caution in severe hepatic impairment due to risk of fluid overload and hyperglycemia.
No dose adjustment required for hepatic impairment; acyclovir is minimally metabolized by the liver.
Intravenous; weight-based dose: 5-10 m L/kg; infusion rate: 2-6 m L/kg/hour; adjust based on age, weight, and clinical status; maximum 100 m L/kg/day in term neonates.
Neonates (0-3 months): 10 mg/kg IV every 8 hours for HSV; Infants and children (3 months-12 years): 10 mg/kg IV every 8 hours for HSV, 20 mg/kg IV every 8 hours for VZV; maximum dose 500 mg/m² per dose.
Elderly: use lowest effective dose; infusion rate: 50-100 m L/hour; monitor for fluid overload, hyperglycemia, and electrolyte imbalance due to decreased renal and cardiac function.
Elderly patients may have reduced renal function; adjust dose based on Cr Cl and monitor for neurotoxicity (e.g., confusion, hallucinations).
Not applicable; no FDA black box warning for this combination product.
None.
Monitor serum glucose and electrolytes, especially in patients with diabetes mellitus or renal impairment,Avoid use in patients with known hypersensitivity to corn or corn products,Risk of fluid overload in patients with heart failure or renal insufficiency,Use with caution in patients with hyperglycemia, hyponatremia, or hypernatremia,Do not administer simultaneously with blood products
Renal impairment: Dose adjustment required; monitor renal function.,Neurotoxicity: May cause agitation, hallucinations, confusion, seizures (especially in elderly or renally impaired).,Crystalluria: Risk increased with rapid infusion or dehydration; ensure adequate hydration.,Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP): Rare but serious, reported in immunocompromised patients.,Pregnancy: Use only if clearly needed (Category B).
Hyperglycemia,Hypernatremia,Hypersensitivity to dextrose or sodium chloride,Patients with known allergy to corn
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.,Neonates: Use of bacteriostatic water-containing preparations (e.g., benzyl alcohol) is contraindicated.
No significant food interactions; however, dietary sodium intake should be considered in patients with hypertension or edema.
No specific food interactions. Adequate fluid intake is recommended to prevent renal toxicity. Avoid concurrent use of nephrotoxic substances (e.g., certain NSAIDs, aminoglycosides) without medical supervision.
Dextrose 5% and sodium chloride 0.225% is considered compatible in pregnancy when used as a vehicle or for correction of fluid and electrolyte disturbances. No teratogenic effects are expected at standard infusion rates. However, excessive administration may cause maternal hyperglycemia, which can lead to fetal hyperinsulinism and neonatal hypoglycemia. No known structural teratogenicity.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; use only if clearly needed.
Dextrose and sodium chloride are normal constituents of breast milk. Infusion of this solution does not pose a risk to the nursing infant. No M/P ratio data available; both components are naturally present in human milk.
Acyclovir excreted in breast milk at low levels; M/P ratio unknown. Typical infant dose ~0.6 mg/kg/day (2-3% of maternal IV dose). No adverse effects reported in breastfeeding infants. Compatible with breastfeeding; caution with high maternal doses.
Pregnancy induces increased plasma volume and glomerular filtration rate, which may require higher infusion rates to achieve desired correction. However, standard dosing is typically adequate; adjust based on clinical response and serum electrolyte monitoring.
Increased renal clearance and volume of distribution in pregnancy may reduce acyclovir exposure. No dose adjustment routinely recommended; however, higher doses or more frequent dosing may be considered for severe infections. Monitor therapeutic response.
Use cautiously in pediatric and elderly patients to avoid fluid overload and electrolyte imbalance. Monitor serum sodium, glucose, and osmolarity in patients with renal impairment or hyperglycemia. Do not administer if solution is discolored or contains particulates.
Acyclovir in sodium chloride 0.9% preservative-free is for IV administration only; do not administer IM or SC. Infuse over at least 1 hour to prevent renal tubular damage. Monitor renal function and adjust dose in renal impairment (Cr Cl <50 m L/min). Ensure adequate hydration (e.g., 500 m L IV fluids per gram acyclovir) to reduce risk of crystalluria. In obese patients, use ideal body weight for dosing. Phlebitis at infusion site is common; rotate sites.
Report signs of fluid overload (swelling, rapid weight gain, shortness of breath).,Advise patients with diabetes that this solution contains dextrose and may affect blood glucose levels.,Inform patients that intravenous administration requires careful monitoring by healthcare professionals.
This medication is given intravenously (into a vein) to treat viral infections.,Drink plenty of fluids before and during treatment to prevent kidney problems.,Report any pain, redness, or swelling at the injection site, or any lower back pain.,Tell your healthcare provider if you have kidney disease or are taking other medications that can affect the kidneys.,This drug does not cure herpes infections but helps reduce symptoms and recurrence.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 5% AND SODIUM CHLORIDE 0.225% vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, answered by our medical review team.
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% is a Electrolyte that works by Dextrose provides a source of calories and acts as a substrate for cellular metabolism, replenishing glucose stores. Sodium chloride provides electrolytes for maintenance of osmotic pressure and fluid balance.. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is a Electrolyte that works by Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 5% AND SODIUM CHLORIDE 0.225% and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 5% AND SODIUM CHLORIDE 0.225% is: Intravenous; adult dose is 500-1000 m L at a rate of 100-200 m L/hour; frequency depends on fluid and electrolyte needs; maximum rate up to 400 m L/hour in hypovolemic states.. The standard adult dose of ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is: 5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DEXTROSE 5% AND SODIUM CHLORIDE 0.225% and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DEXTROSE 5% AND SODIUM CHLORIDE 0.225% is classified as Category A/B. Dextrose 5% and sodium chloride 0.225% is considered compatible in pregnancy when used as a vehicle or for correction of fluid and electrolyte disturbances. No teratogenic effects . ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.